Evidence map›Paper›PMID 37720099›Full record

ArticleiScience2023

Thomas C Harper, Elaine M Oberlick, Tomas J Smith, Duncan E Nunes, Mark-Anthony Bray, Seonmi Park, Corey D Driscoll, Sarah F Mowbray, Christophe Antczak

Abstract read
In one paragraph

Article in iScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. CAR-engineered neutrophils derived from induced pluripotent stem cells: a new frontier in cellular immunotherapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Thomas C HarperChemical Biology and Therapeutics, Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
Elaine M OberlickRespiratory Disease Area, Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
Tomas J SmithRespiratory Disease Area, Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
Duncan E NunesRespiratory Disease Area, Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
Mark-Anthony BrayChemical Biology and Therapeutics, Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
Seonmi ParkChemical Biology and Therapeutics, Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
Corey D DriscollRespiratory Disease Area, Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
Sarah F MowbrayRespiratory Disease Area, Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
Christophe AntczakChemical Biology and Therapeutics, Novartis Institutes for BioMedical Research, Cambridge, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human pluripotent stem cell (hPSC)-derived tissues can be used to model diseases in cell types that are challenging to harvest and study at-scale, such as neutrophils. Neutrophil dysregulation, specifically neutrophil extracellular trap (NET) formation, plays a critical role in the prognosis and progression of multiple diseases, including COVID-19. While hPSCs can generate limitless neutrophils (iNeutrophils) to study these processes, current differentiation protocols generate heterogeneous cultures of granulocytes and precursors. Here, we describe a method to improve iNeutrophil differentiations through the deletion of

Indexed as

ImmunologyMethodology in biological sciencesStem cells research

Identifiers

PMID37720099
PMCPMC10500457

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.